XNAS
SABS
Market cap262mUSD
Oct 08, Last price
2.89USD
1D
0.35%
1Q
-24.35%
IPO
-97.15%
Name
SAB Biotherapeutics Inc
Chart & performance
P/E
19.81
P/S
—
EPS
0.15
Div yield, %
—
Shrs. gr., 5y
86.74%
Rev. gr., 5y
-17.42%
Revenues
0
-100.00%
Net income
13m
P
CFO
-45m
L+30.57%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Key people
Samuel Reich
Chief Executive Officer, Director · since 2026
David Link
Independent Vice Chairman of the Board · since 2018
Lucy To
Chief Financial Officer · since 2024
Christoph Bausch
Chief Operating Officer · since 2022
Alexandra Kropotova
Chief Medical Officer · since 2022
Eddie Sullivan
President, Director · since 2024
Katie Ellias
Independent Director · since 2023
Scott Giberson
Independent Director · since 2022
Independent Director · since 2023
Andrew Moin
Independent Director · since 2023
William Polvino
Independent Director · since 2019
Jay Skyler
Independent Director · since 2024
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||